• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

    6/2/24 10:15:00 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BLUE alert in real time by email

    CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy.

    2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio. We have invested in nine nationally recognized companies employing 100+ people and have collectively raised over 85 million dollars. We build and invest in biotechnology, medical devices, and digital health companies with a core mission of advancing health equity and addressing large unmet medical needs.

    2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

    Dr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in the biopharmaceutical industry leading clinical development of multiple medicines across various therapeutic areas. At Chinook Therapeutics, she advanced the pipeline as Senior VP of Product Development and Strategy, leading to a $3.2 billion acquisition by Novartis. Previously, she was VP of Global Clinical Development and Head of Nephrology at Otsuka Pharmaceuticals. She founded and presides over Women of Color in Pharma (WOCIP®), advancing health equity and transforming the biopharmaceutical landscape for women of color. She has received multiple awards, including the MM&M Platinum Award for Outstanding Contribution to Healthcare and WOCIP's Global Icon Award. She also has been identified as one of the pharmaceutical industry's top 100 inspiring people by PharmaVoice and spotlighted as one of "The Most Influential People in Biopharma" by Fierce Pharma. Dr. Jones-Burton serves on the boards of bluebird bio (NYSE:BLUE) and the American Kidney Fund. She holds a Doctor of Medicine (MD) and a Master of Science (MS) in epidemiology and preventive medicine, both awarded by the University of Maryland School of Medicine. She also earned a Bachelor of Arts degree from Washington University in St. Louis.

    Paul Burton, JD, MBA, Managing Partner at 2Flo, commented, "This is an exciting and pivotal point in 2Flo's growth. Charlotte's addition to the team enhances our robust pipeline, which includes nearly ten portfolio companies such as Cancer IQ, Temprian Therapeutics, and Vivacelle Bio. As part of our mission as investors and health equity advocates in areas of high unmet need, we are proud to support these companies through significant milestones, including the upcoming Phase 3 trial for Vivacelle's treatment for hypovolemia induced by septic shock. With Charlotte's expertise and the extensive experience of our 40+ advisors, we believe we can further leverage our platform's strengths to benefit both current and prospective portfolio companies with the goal of generating meaningful returns for our stakeholders."

    Dr. Jones-Burton's commitment to advancing health equity through drug development and patient advocacy perfectly aligns with 2Flo's mission of investing in breakthrough innovations for a healthier future for all. Her experience positions her to drive growth within the life sciences portfolio. "I am thrilled to join 2Flo Ventures and contribute to the firm's mission to accelerate equitable innovation in healthcare through sound investments and adequate guidance," said Dr. Jones-Burton. "I am particularly drawn to 2Flo's intense focus on supporting its portfolio companies to develop best-in-class therapies and its desire to advance health equity. I look forward to helping lead our team as we take on big challenges with urgency, rigor, and creativity, stated Dr. Jones-Burton, New Partner and Head of Life Science Product Development and Strategy.

    Harven DeShield, PhD, JD, MSc, CEO of Vivacelle Bio, added, "I am honored to have initially worked alongside Charlotte during her previous advisory role with the 2Flo team. In a short time, she helped us develop sustainable and highly productive clinical and regulatory strategies, ensuring streamlined advancement of our programs. Looking ahead, we are excited to have her as a full resource through 2Flo's unique venture studio model. We believe Charlotte and the entire 2Flo team fully embrace and work towards securing health equity and access for all. We are proud to be part of their ecosystem and to propel their mission forward."

    The 2Flo Ventures team is supported by an extensive cohort of advisors who have deep life sciences experience spanning the full lifecycle of a company's maturity and development.

    About 2Flo Ventures

    2Flo Ventures is a Chicago based early-stage venture capital firm and startup studio. We have invested in nine nationally recognized companies employing 100+ people and have collectively raised over 85 million dollars. We build and invest in companies across biotechnology, medical devices, and digital health with a core mission of advancing health equity and addressing large unmet medical needs.

    Contact: Ibraheem Alinur, [email protected]

    Charlotte Jones-Burton MD, MS

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/2flo-ventures-announces-addition-of-renowned-life-sciences-executive-charlotte-jones-burton-md-ms-as-a-partner-302161397.html

    SOURCE 2Flo Ventures

    Get the next $BLUE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BLUE

    DatePrice TargetRatingAnalyst
    2/24/2025Underweight → Neutral
    Analyst
    2/24/2025$29.00Overweight
    Analyst
    11/18/2024Neutral → Underweight
    Analyst
    11/15/2024Neutral → Underweight
    JP Morgan
    11/15/2024$3.00 → $0.50Buy → Neutral
    BofA Securities
    8/15/2024Overweight → Neutral
    JP Morgan
    12/11/2023Hold → Reduce
    HSBC Securities
    12/8/2023$3.00 → $7.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business & Legal Officer Vittiglio Joseph returned 5,625 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 6:02:16 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Agwunobi John O returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 5:46:09 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vachon Mark returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 5:38:38 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

      New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer

      6/2/25 8:34:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

      All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right ("CVR") if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December

      5/30/25 8:30:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company") today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Additionally, the Company today announced that Ayrmid Ltd. ("Ayrmid") has confirmed it will not submit a binding proposal to acquire bluebird following bluebird's amended agreement with Carlyle and SK Capital. The bluebird Board of Directors

      5/27/25 8:30:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bluebirdbio upgraded by Analyst

      Analyst upgraded Bluebirdbio from Underweight to Neutral

      2/24/25 7:05:14 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Analyst initiated coverage on Bluebirdbio with a new price target

      Analyst initiated coverage of Bluebirdbio with a rating of Overweight and set a new price target of $29.00

      2/24/25 7:04:33 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bluebirdbio downgraded by Analyst

      Analyst downgraded Bluebirdbio from Neutral to Underweight

      11/18/24 4:13:05 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Financials

    Live finance-specific insights

    See more
    • bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

      - 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence

      11/14/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,

      11/6/24 4:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

      Actions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET Following a comprehensive review of its operations, bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the Company's workforce of approximately 25%. The Company's cash flow break-even tar

      9/24/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

      For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

      8/17/22 2:12:27 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    SEC Filings

    See more
    • SEC Form 15-12G filed by bluebird bio Inc.

      15-12G - bluebird bio, Inc. (0001293971) (Filer)

      6/12/25 6:05:15 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by bluebird bio Inc.

      EFFECT - bluebird bio, Inc. (0001293971) (Filer)

      6/4/25 12:15:02 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by bluebird bio Inc.

      POS AM - bluebird bio, Inc. (0001293971) (Filer)

      6/2/25 10:37:46 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Leadership Updates

    Live Leadership Updates

    See more
    • 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

      CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in th

      6/2/24 10:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Appoints O. James Sterling as Chief Financial Officer

      bluebird bio, Inc. (NASDAQ:BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. "We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets will position us well as we work to prove the commercial gene therapy model, and demonstrate progress on our path to profitability," said Andrew Obenshain, chief executive officer, bluebird bio. "It is an honor to be joining bluebird bi

      5/29/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

      Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

      12/6/23 8:00:00 AM ET
      $BLUE
      $TSVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:39:36 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:27:32 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 10:32:08 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care